The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 31, 2010
Filed:
Nov. 14, 2007
Clark Pan, Sudbury, MA (US);
Steve Roczniak, Madison, AL (US);
Jeffrey Michael Greve, Berkeley, CA (US);
Stephanie L. Yung, San Francisco, CA (US);
Malinda Longphre, Oakland, CA (US);
Teresa Mo-fun Wong, Lafayette, CA (US);
Adrian Tomkinson, El Cerrito, CA (US);
David Boisvert, El Cerritto, CA (US);
Elise Burmeister-getz, Berkeley, CA (US);
Kathy Delaria, Walnut Creek, CA (US);
Clark Pan, Sudbury, MA (US);
Steve Roczniak, Madison, AL (US);
Jeffrey Michael Greve, Berkeley, CA (US);
Stephanie L. Yung, San Francisco, CA (US);
Malinda Longphre, Oakland, CA (US);
Teresa Mo-Fun Wong, Lafayette, CA (US);
Adrian Tomkinson, El Cerrito, CA (US);
David Boisvert, El Cerritto, CA (US);
Elise Burmeister-Getz, Berkeley, CA (US);
Kathy Delaria, Walnut Creek, CA (US);
Aerovance, Inc., San Diego, CA (US);
Abstract
This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.